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Background: Oxaliplatin-based regimens induce a potential risk of hypersensitivity reaction (HSR), with incidence
varying from 10% to 25% and lack of clearly identified risk factors. The present study aimed to assess incidence and
risk factors in HSR.
Methods: All patients treated with oxaliplatin in the Medical Oncology Department of the Lyon Sud University
Hospital (Hospices Civils de Lyon, France) from October 2004 to January 2011 were enrolled. Incidence and severity
of HSR were analyzed retrospectively and the potential clinicopathological covariates were tested on univariate and
multivariate analysis.
Results: A total of 1,221 doses of oxaliplatin were administered for 191 patients, 8.9% of whom experienced an
HSR. Seventeen HSRs were observed, with 1.6% grade 3 and no grade 4 events. The first reaction appeared after a
median of 3 oxaliplatin infusions. Using univariate analysis, HSR was associated with younger age (mean age,
56.2 years; p = 0.04), female gender (p = 0.01) and prior exposure to platinum salts (p = 0.02). No increased risk was
associated with mean dose or with presence of atopic background. Multivariate analysis confirmed that women
were at higher risk of oxaliplatin HSR than men (p < 0.05). Reintroduction of oxaliplatin was effective in 64.7% of
hypersensitive patients using an appropriate premedication strategy. Patients who experienced a grade 3 HSR were
not rechallenged.
Conclusion: The risk of developing oxaliplatin HSR should not be underestimated (8.9% of patients). The medical
team’s vigilance should be increased with women, younger patients and patients with prior exposure to platinum
salts.
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Chemotherapy agents can induce hypersensitivity reac-
tion (HSR), reducing the use of critical drugs in fragile
patients for fear of inducing severe reaction and possibly
death. However, with improved outcomes in cancer care,
longer patient survival and extended treatment courses,
patients are exposed to drugs more frequently and for
longer periods, increasing the risk of sensitization and of
HSR. Prevention and management of acute infusion* Correspondence: catherine.rioufol@chu-lyon.fr
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reproduction in any medium, provided the orreactions in oncology remain essential [1], particularly
with platinum agents (carboplatin, cisplatin and oxalipla-
tin) [2]. HSR should be an important concern, due to its
potential life-threatening risk and the subsequent treat-
ment withdrawal [3].
Oxaliplatin, a third-generation platinum agent, has
been approved for the treatment of metastatic colorectal
cancer and for adjuvant treatment in stage-III colon can-
cer [4]. It is also used worldwide in other malignancies,
such as ovarian cancer [5]. As colorectal cancer is the
third most common cancer in the world and the second
leading cause of cancer death in western countries, its
treatment is currently a public health priority and oxali-
platin represents a key chemotherapeutic agent [6].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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than to cisplatin and carboplatin. However the increasing
use of oxaliplatin in clinical practice shows significant inci-
dence, varying from 10% to 23.8% [3,7-13]. Identifying pa-
tients with high risk of oxaliplatin-HSR is a major clinical
issue and several studies assessed risk factors, although
with heterogeneous results [3,7,9,10,14]. Moreover, Asian
populations were mostly investigated [3,7,8,10,12-15], but
only some studies evaluated the risk factors using multi-
variate analysis [3,7,9,12].
The aim of this retrospective cohort study was to




All patients who received at least one dose of oxaliplatin
in the Medical Oncology Department of the Lyon Sud
University Hospital (Hospices Civils de Lyon, France)
over a 6-year period from October 2004 to January 2011
were identified using the pharmaceutical software dedi-
cated to antineoplastic preparation. Routine premedi-
cation before oxaliplatin infusion included 120 mg of
methylprednisolone given intravenously and antiemetic
prophylaxis.
The following clinical data were collected from med-
ical files: sex, age, history of allergy, oxaliplatin HSR,
type of cancer, previous exposure to platinum agents,
and oxaliplatin exposure during the study period (total
number of courses, doses and cumulative dose), and
treatment line number.
Data from patients who experienced oxaliplatin-asso-
ciated HSR were compared to that of controls patients
who received oxaliplatin without experiencing HSR.
For the purposes of the present study, HSR was defined
as any unexpected adverse manifestation including non-
allergic drug hypersensitivity and drug allergy reactionsTable 1 Clinical severity scale of immediate reactions










NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Evelike the typical symptoms of IgE-mediated reactions,
including cutaneous symptoms such as palmar or facial
flushing, respiratory symptoms such as shortness of breath,
and cardiovascular symptoms such as any alteration in
pulse or blood pressure [16]. Expected side-effects, such as
chemotherapy-induced nausea or vomiting and diarrhea,
were excluded. Severity was graded according to the Ring
and Messmer’s classification [17] and the National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE v 4) because of its frequent use by
medical oncologists worldwide (Table 1). The outcome
data was also recorded for each patient.
Statistical analysis
Clinicopathological variables potentially associated with
oxaliplatin HSR were subjected to univariate analysis.
Statistical analysis was carried out using Wilcoxon’s test
to determine whether age or mean dose were associated
with hypersensitivity. The other factors (sex, prior pla-
tinum exposure and atopic background) were evaluated
using Fisher’s exact test.
For multivariate analysis, a logistic regression model
was applied. All variables with a p-value ≤ 0.1 on univari-
ate analysis were considered candidates for multiple
logistic regression. Two-sided p values exceeding 0.05
were considered statistically significant. Statistical ana-
lysis used SAS software, version 8.
Since data were collected retrospectively and that pa-
tients’ management was not modified, according to the
French law (n°2004-806, 9th august 2004), this study did
not need to be approved by a research ethics committee
[18]. It was conducted in accordance with the law on
data protection (n°2004-801, 6th august 2004).
Results
A total of 191 patients treated with oxaliplatin were
included. Patient characteristics are listed in Table 2.According to NCI-CTCAE
Mild transient reaction with no infusion interruption
Therapy or infusion interruption indicated but responds promptly
to symptomatic treatment (antihistamines, corticosteroids,
narcotics, IV fluids)
Prolonged reaction not rapidly responsive to symptomatic
medication and/or brief interruption of infusion.
Recurrence of symptoms following initial improvement
Hospitalization indicated for clinical sequelae
Life-threatening consequences with urgent intervention indicated
Death
nts.
Table 2 Patient characteristics
Patient characteristics (n = 191) Mean (range) n (%)
Age (years) 62.4 (23–84)
Sex, male 78 (41)
















GEMOX (oxaliplatin and gemcitabine) 47 (25)
Oxaliplatin alone 5 (3)
TOMOX(oxaliplatin and raltitrexed) 12 (6)
Other2 12 (6)
Total infusion courses 6.4 (1–18)
Oxaliplatin dose (mg/m2) 85.3 (42–160)
1Includes: appendix (2), gallbladder (4), liver (2), mouth (1), oesophagus (2),
endometrium (1) and unknown primary (6).
2Includes: 2 ELOGEM (combination of oxaliplatin and gemcitabine), 2 EOX
(combination of oxaliplatin, epirubicin and capecitabine), 2 FOLFIRINOX
(combination of oxaliplatin, irinotecan, 5-fluorouracil and leucovorin),
1 FOLFOX6 (combination of oxaliplatin, 5-fluorouracil and leucovorin),
2 FOLFOX7 (combination of oxaliplatin, 5-fluorouracil and leucovorin),
1 patient treated with oxaliplatin and epirubicine, 1 oxaliplatin with cetuximab
and 1 XELOX (combination of oxaliplatin and capecitabine).
Table 3 Hypersensitivity reactions to oxaliplatin
Hypersensitivity
reactions to oxaliplatin
Hypersensitivity reactions 17 (8.9%)
Severity according to Ring and Messmer [17]
Grade 1 events 12 (6.3%)
Grade 2 events 2 (1.0%)
Grade 3 events 3 (1.6%)
Grade 4 events 0
Severity according to to NCI-CTCAE
Grade 1 events 5 (2.9%)
Grade 2 events 9 (4.7%)
Grade 3 events 3 (1.6%)
Grade 4 events 0
Grade 5 events 0
Cycle number at event
Median (range) 3 (1–13)
NCI-CTCAE: National Cancer Institute Common Terminology Criteria for
Adverse Events.
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treated with a FOLFOX4 regimen (combination of oxali-
platin, 5-fluorouracil and leucovorin). During the 6-year
follow-up, 17 patients experienced an HSR to oxaliplatin,
representing an incidence of 8.9% of all treated patients
(Table 3). A total of 1,221 doses of oxaliplatin were admi-
nistered, with 1.8% overall frequency of HSR. Patients re-
ceived median of 4.7 infusions, with a mean 85.3 mg/m2
oxaliplatin per infusion. First HSR appeared after median
of 3 infusions, and before the 7th course in most patients
(80%). Among the 7 patients who developed a first HSR at
the 1st or 2nd course, 3 have already been exposed to
platinum agents. Sixteen of the 17 patients with HSR were
women (94%) and 2 of them were treated for ovarian
cancer.
During the first reaction, the most common effects
were flushing (10 patients), urticaria (4 patients) and
fever (4 patients). Two patients experienced dyspneawithout bronchospasm. Severity of HSRs according to the
Ring and Messmer’s classification and the National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE v 4) was similar (Table 3). Most
reactions were moderate but three patients presented
grade 3 HSRs with hypotension, hypothermia and symp-
tomatic larynx spasm (1 patient), acute hypertension,
symptomatic larynx spasm and dyspnea (1 patient), and
hypotension, bradycardia, hypothermia and fainting (1 pa-
tient). There was no grade 4 event (heart failure or res-
piratory arrest which required urgent intervention) and no
death. Nine patients responded promptly to symptomatic
treatments (antihistamines, corticosteroids, narcotics or
IV fluids) and 3 patients had a more prolonged reaction
not rapidly responsive to symptomatic medications and/or
brief interruption of infusion.
After their first HSR episode, 13 patients (76%) were
rechallenged with a mean 4.8 further cycles of oxaliplatin,
associated in most cases with strengthened premedication
including antihistamines and higher-dose corticosteroids.
Patients who experienced a grade 3 HSR were not rechal-
lenged. Four (30.8%) experienced another HSR at the
following course: 1 second reaction in 3 patients and 2 in
another patient, which 1 required definitive withdrawn of
oxaliplatin. A total 22 HSRs occurred in 17 patients and
required definitive withdrawn of oxaliplatin in 2 patients.
Clinical signs and severity were generally similar in first
and repeat episodes. Three clinicopathological parameters
emerged as potential risk factors for oxaliplatin HSR using
univariate analysis (Tables 4 and 5). Patients from the
HSR group were younger (mean age, 56.2 years) than
controls (mean age, 62.6 years; p < 0.05). The rate of
Table 4 Results of univariate analysis (n = 191)
Patients (n) HSR (n) HSR (%) p value1
Sex
Female 113 16 14.2 0,0147
Male 78 1 1.3
Prior exposure to platinum salts
Yes 45 8 17.8 0,0220
No 146 9 6.2
Atopic background
Yes 32 4 12.5 0,4367
No 159 13 8.2
1Fischer exact test.
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with 14.2% of all women treated with oxaliplatin having
reactions compared to only 1.3% of all men. Thirdly, HSR
was more frequent in patients previously treated with pla-
tinum salts (p < 0.05). Mean oxaliplatin dose and presence
of atopic background were not significantly associated
with HSR. Using multivariate analysis, sex was the only
remaining significant covariate, thereby confirming that
women are at higher risk of oxaliplatin than men (p < 0.05).
Discussion
Hypersensitivity reactions to antineoplastic agents are
commonly overlooked. However, for some drugs, particu-
larly L-asparaginase, taxanes and platinum salts, hypersen-
sitivity may lead to the withdrawal of the chemotherapy,
thereby reducing the number of therapeutic options. The
incidence of oxaliplatin HSR is rising as a consequence of
its increased clinical use. Given the limited number of
active agents in colorectal malignancy, it is now necessary
to understand this kind of reactions and ways of prevent
them [19]. The present retrospective study of 191 French
patients aimed at bringing new insights to the clinical
features of oxaliplatin HSR and its risk factors.
Incidence of oxaliplatin HSR and number of previous
cycles appeared to differ from other reports, with lower
incidence (8.9%) and earlier onset (before the 6th course),
compared to 10–23.8% incidence [3,7-11,13,20] and onset
mostly after 6–10 courses [3,10,14,20-22]. As previously
described, age and female gender were identified as risk
factors [7,9,13]. Interestingly, we showed that 94% of
hypersensitive patients were women, finding which was
not reported yet. The reasons for this increased risk
amongst females are not known. However, it is wellTable 5 Results of univariate analysis (n = 191)
Patients with HSR (n = 17)
Mean age (years) 56.2 ±10.5
Mean oxaliplatin dose (mg/m2) 88.5 ±15.2
2Wilcoxom’s test.established that, for unknown reasons, anaphylaxis is
more frequent in women. Kim et al. suggest that an asso-
ciation between female gender and younger age may be
explained by a possible role of hormonal influences [9].
Another hypothesis could be the important proportion of
women (89%) among patients with a previous exposure to
platinum agents which is a risk factor of oxaliplatin HSR
in univariate analysis in this study. We also investigated
the influence of prior exposure to platinum salts. Previous
infusions appeared as a risk factor for oxaliplatin HSR.
The effect of the platinum-free interval on the incidence
and severity of HSR to platinum-containing agents is still
a matter of discussion [7]. The impact of concomitant
drugs on the risk of HSR is still an issue. In the present
study, among 5 patients received oxaliplatin concomi-
tantly with cetuximab, known to induce reaction at the
time of administration, 1 patient developed an HSR. Our
patients were treated with 14 different regimens which
prevent us to assess the involvement of associated treat-
ment due to a lack of power. The efficiency of preme-
dication on HSR is naturally expected. A recent study
demonstrated a significant improvement of tolerance with
increased doses of dexamethasone and antihistamine [23].
Our patients were systematically treated with 120 mg
methylprednisolone before oxaliplatin infusion, leading to
a lower incidence of HSR. Several studies assessed the
effect of re-exposure to oxaliplatin with or without pre-
medication. In most cases, steroids plus antihistamines
and prolongation of oxaliplatin infusion were helpful. A
secondary prevention regimen comprising 40 mg famoti-
dine, 20 mg dexamethasone plus 50 mg diphenhydramine
was investigated before re-exposure to oxaliplatin in 30
patients with prior HSR: oxaliplatin was well tolerated in
19 of 30 patients (63.3%) for at least 2 cycles [20].
Management of patients with oxaliplatin HSR remains
the question of importance in terms of possible thera-
peutic options. In the present study, 13 of the 17 hyper-
sensitive patients were re-exposed to oxaliplatin; only 4
developed further reactions. Nevertheless, patients who
experienced a grade 3 HSR were not rechallenged. Con-
sistently with previous reports, reintroduction of oxali-
platin is generally possible in grade 1/2 hypersensitive
patients using an appropriate premedication strategy: i.e.
anti-histamine and/or steroids, and reduced infusion flow
[24-26]. But uniform approach to prevent oxaliplatin HSR
has not been established and reintroduction remains asso-
ciated with recurrence of HSR, which requires permanent
withdrawal of oxaliplatin infusion with obvious harmfulPatients without HSR (n = 174) p value2
62.6 ±12 0.0405
87.4 ±13.1 0.7473
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vention are needed. Consistently with our results, rein-
forced premedication could be assessed after 3 courses
of oxaliplatin (median of our study) for example or for
women with prior exposure to platinum salts. Moreover,
when oxaliplatin treatment is considered fundamental for
the patient after severe HSR, desensitization should be
performed. The need to offer first-line therapy has urged
the clinical development of rapid desensitization, which
allows hypersensitive patients to be re-treated with medi-
cations. Such protocols are safe and effective and allow
patients to continue with the treatment that initially
caused an HSR [27,28].
Finally, another therapeutic option is the switch for
carboplatin or cisplatin, in case of gynecological malig-
nancies for example. Successful replacement of carbo-
platin by cisplatin has been demonstrated but cases of
severe reactions have also been reported [29]. The inci-
dence of cross reaction with oxaliplatin is not known
and less described. Some authors suggested to perform
skin tests to exclude cross-reactivity before substituting
one platinum analog for another [30,31]. Skin tests have
been reported to predict oxaliplatin allergic HSR [32],
but are rarely used in daily practice. Indeed there are
time-consuming, uncomfortable for the patient and only
available in some drug allergy care centers. Nonetheless,
skin tests and the basophile activation test contribute to
identifying the mechanism of HSR which remains un-
clear. Because of HSR usually occurs after multiple infu-
sions, platinum agents are thought to induce a type I
response mediated by IgE, followed by the release of
histamine and cytokines. Recent studies have suggested
the involvement of type II and III reactions [33]. Further
analysis of the mechanism may lead to the development
of effective therapeutic strategies.
Several limitations of this study should be noted. As
this was a retrospective study, hypersensitivity symptoms
were not actively pursued. Some medical records were
insufficient and the incidence of HSR was probably
underestimated. The number of study subjects is small,
so data presented should be interpreted with caution.
Conclusions
Given the frequency and potential severity of oxaliplatin
HSR, identification of risk factors could be of therapeutic
benefit. In the present analysis, women, younger patients
(mean age, 56.2 years) and patients who had experienced
a prior exposure to platinum salts presented increased
risk. Reintroduction of oxaliplatin is generally possible in
grade 1/2 hypersensitive patients using an appropriate
premedication strategy but uniform approach to prevent
oxaliplatin HSR has not been established and reintroduc-
tion remains associated with recurrence of HSR, which
requires permanent withdrawal of oxaliplatin infusion.The risk of developing HSR during oxaliplatin treatment
should not be underestimated. Patients need to be in-
formed about clinical manifestations, so they can be han-
dled early by physicians and nursing staff. These findings
underline that a close monitoring should be systematic
during oxaliplatin infusion, especially if risk factors are
identified.
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